Navigation Links
Forma in Medical News

The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster

WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July 20 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and FORMA Therapeutics today announced a partnership to accelerate LLS's pipeline of research projects entering late pre-clinical development. The collaboration will beg...

Hanger Orthopedic Group, Inc. Reports $0.26 Pro Forma EPS on 8.6% Sales Growth for the Fourth Quarter 2008

Provides 2009 Revenue and EPS Guidance BETHESDA, Md., Feb. 10 /PRNewswire-FirstCall/ -- Hanger Orthopedic Group, Inc. (NYSE: HGR ) announced net sales of $185.5 million for the quarter ended December 31, 2008, an increase of $14.7 million, or 8.6%, from $170.8 million in the prior year's...

Lilly Files Form 8-K/A Detailing Pro Forma Impact of ImClone Acquisition

INDIANAPOLIS, Jan. 12 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today filed a Form 8-K/A with the U.S. Securities and Exchange Commission (SEC) detailing the pro forma impact of the company's recently- completed acquisition of ImClone Systems. The Form 8-K/A is available o...

Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results

...curities, available-for-sale. In July 2009, Orexigen completed a public offering, the estimated net proceeds of which totaled $81.6 million. The pro forma balance of cash, cash equivalents and investments, available-for-sale, including the estimated net proceeds of the public offering, is $127.6 million....

Gentiva Reports Second Quarter 2009 Results

...9 outlook represents an increase in net revenues of 12% to 14% and an increase in diluted earnings per share of 45% to 50% when compared with 2008 pro forma financial results, which reflect the Company's performance as if the CareCentrix divestiture had occurred at the beginning of fiscal 2008. The 2009 ou...

Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance

... 2009 were $0.31 per diluted share compared to pro forma earnings per share for the same period in 2008 of ...r diluted share, a 24.0% increase. The pro forma diluted EPS for the second quarter 2008 assume tha...llion, or $0.46 per diluted share, compared to pro forma net income applicable to common stock of $11.6 mil...

Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance

... to $1.06 (reported); 19% EPS Growth to $1.12 (pro forma non-GAAP) Full-Year 2009 Reported EP... Revised to $4.14 to $4.24 per share Pro forma non-GAAP EPS Guidance Range Raised to $4.20 to $4.... reported basis, and raised its full-year 2009 pro forma non-GAAP earnings per share guidance range to $4.2...

JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc.

...losing of the transaction remains subject to (a) CardioGenics closing on private placements of not less than $1,500,000; (b) the completion of the pro forma financial statements for the transaction based on CardioGenics' and JAG Media's relevant financial statements; (c) the CardioGenics shareholders and d...

JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc.

...o the remaining closing matters, such as the completion of the required pro forma financials for the transaction, the Current Report on Form 8-K for the tran...ivate placements of not less than $1,500,000; (c) the completion of the pro forma financial statements for the transaction based on CardioGenics' and JAG Med...

CareFusion Names Robert Friel to Board of Directors

...e company has applied to have its shares of common stock listed on the New York Stock Exchange under the ticker symbol "CFN." (1) Fiscal 2008 pro forma revenue, Amendment No. 3 to Form 10 Registration Statement filed on June 26, 2009. Cautions Concerning Forward-Looking Statements This news ...

More>>

Forma in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... strategy and as a result reported $669,000 of pro forma net income for the quarter ended June 30, 2009, a ... the same period in 2008. Isis also reported a pro forma net operating loss of $1.3 million for the second quarter compared to pro forma net operating income of $4.6 million for the same ...

The Yolanda Adams Morning Show and Radio One Gospel Stations Raise More Than $1 Million During National Radiothon Benefiting St. Jude

...ion's largest radio broadcasting companies and the largest radio broadcasting company that primarily targets African-American and urban listeners. Pro forma for recently announced transactions, Radio One owns and/or operates 53 radio stations located in 16 urban markets in the United States. Additionally, ...

FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria

...sition in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. About sanofi-aventis Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to ...

Keppra XR(TM) Extended-Release Tablets Filed with the FDA

...sition in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and through its affiliate. SCHWARZ PHARMA AG (Monheim, Germany) is a member of the UCB Gro...

UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets

...sition in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and through its affiliate, owns approx. 89% of the shares of SCHWARZ PHARMA AG. SCHWARZ PH...

CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year

...sition in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB is listed on the Euronext Brussels Exchange and owns approx. 88% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA AG (Monheim, Germany) i...

Lilly and Glenmark Pharmaceuticals Announce License Agreement

...er share. Lilly's fourth-quarter and full-year pro forma adjusted earnings per share guidance remain unchan... - .31 Include pro forma as if the ICOS acquisition was completed on Ja... - (.03) E.P.S. (pro forma adjusted) $.86 to $.91 $.82 5% ...

Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome

...sition in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB is listed on the Euronext Brussels Exchange and owns approximately 88% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA AG (Monheim, Germ...

Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinson's Disease

...sition in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB is listed on the Euronext Brussels Exchange and owns approximately 88% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA AG (Monheim, Germ...

More>>

Forma in Medical Products

-40 Plasma Freezer

Description:... Model 8624 is UL Listed, CSA Certified, CE Marked. Thermo forma Plasma Freezers safely store single donor, fresh frozen plasma, and cryoprecipitate. Recorders are standard. Cold wall refrigeration system with 5.0" ...
Company:ThermoFisher Scientific

-30 Plasma Freezer

Description:... Model 8097 is CSA Certified. Thermo forma Plasma Freezers safely store single donor, fresh frozen plasma, and cryoprecipitate. Recorders are standard....
Company:ThermoFisher Scientific

Blood Bank Refrigerator 3866/3868

Description:... Designed for the precise requirements of blood banking and processing applications, Thermo forma Blood Bank Equipment meets American Association of Blood Banks (AABB), American National Red Cross (ANRC) and U.S. Food & Drug Administration (FDA) st...
Company:ThermoFisher Scientific

Blood Bank Refrigerator 3883

Description:... Designed for the precise requirements of blood banking and processing applications, Thermo forma Blood Bank Equipment meets American Association of Blood Banks (AABB), American National Red Cross (ANRC) and U.S. Food & Drug Administration (FDA) st...
Company:ThermoFisher Scientific

Blood Bank Refrigerator 3644

Description:... Designed for the precise requirements of blood banking and processing applications, Thermo forma Blood Bank Equipment meets American Association of Blood Banks (AABB), American National Red Cross (ANRC) and U.S. Food & Drug Administration (FDA) st...
Company:ThermoFisher Scientific

Blood Bank Refrigerator 3881

Description:... Designed for the precise requirements of blood banking and processing applications, Thermo forma Blood Bank Equipment meets American Association of Blood Banks (AABB), American National Red Cross (ANRC) and U.S. Food & Drug Administration (FDA) st...
Company:ThermoFisher Scientific

Blood Bank Refrigerator 3626

Description:... Designed for the precise requirements of blood banking and processing applications, Thermo forma Blood Bank Equipment meets American Association of Blood Banks (AABB), American National Red Cross (ANRC) and U.S. Food & Drug Administration (FDA) st...
Company:ThermoFisher Scientific

Wrist Hand Orthosis

Features:...ion of minor forearm and metacarpal fractures or post-cast fracture immobilization Constructed of rigid polyethylene laminated with soft closed-cell forma lining and contact closure Available in five sizes (x-small thru x-large) in either left or right ...
Company:Corflex, Inc.

More>>

Forma in Biological Technology

Caliper Life Sciences Reports Second Quarter 2009 Results

...revenue growth compared to second quarter 2008 pro forma revenue: Optical Imaging: 17% growth (21...in California and Massachusetts. Pro forma revenue and adjusted net loss per share are non-GA...ts organic revenue growth of 5 to 7% over 2008 pro forma revenue. In addition, the Company reaffirmed its...

GlaxoSmithKline Completes Acquisition of Stiefel

...ducts for 2008 were approximately $900 million and sales of GSK's prescription dermatology products were approximately $550 million. The combined pro forma revenues of approximately $1.5 billion, represent an 8% share of the global prescription dermatology market. Stiefel is committed to improv...

Pharma and Biotech Companies Plug into Singapore's Integrated Research Network

...mouth disease. Massachusetts-based biotech, forma Therapeutics, has also set up its first overseas l...al University (NTU). An emerging biotech company, forma seeks to integrate important new advances in biolo...s and pathways that genomic medicine has revealed. forma will be collaborating with the Experimental Therap...

Kendle Announces First Quarter 2009 Results

...4.1 million or $0.27 per diluted share for the first quarter 2008. On a pro forma basis, net income for the first quarter of 2009 was $0.47 per diluted share...ating to the unwinding of a Pound Sterling foreign currency hedge. Pro forma earnings per share, excluding the impact of APB 14-1 and the additional exp...

Savient Pharmaceuticals Reports First Quarter 2009 Financial Results

...l 2009, we raised $31.0 million from a registered direct offering, which yielded $29.0 million in cash, net of offering and related expenses. Our pro forma cash and short-term investments balance as of March 31, 2009, reflecting receipt of the net proceeds from the April registered direct offering, is $87...

Caliper Life Sciences Reports First Quarter 2009 Results

...rter of 2009 is $28 to $31 million. On an organic basis, the midpoint of this range would result in revenues being approximately flat compared to pro forma revenue of $30.7 million in the second quarter 2008, after taking into account the divested products lines as well as anticipated unfavorable currency...

GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business

...for the treatment of severe psoriasis. GSK's key dermatology brands include: Bactroban, Cutivate and recently launched Altabax . Combined pro forma revenues for the calendar year ended 2008 were approximately $1.5 billion, representing an 8% share of the global prescription dermatology market. Sal...

Gen-Probe Completes Acquisition of Tepnel Life Sciences

...egarding the expected financial results of the acquisition. Tepnel has not reconciled its historical financial statements to U.S. GAAP. All pro forma combined financial information in this press release is based upon a combination of Gen-Probe historical and projected financial information, prepared...

China Sky One Medical, Inc. Provides Update on Filing Form 10-K

...sh compensation expense during 2008. This is the only outstanding issue that has delayed the filing of its annual report on form 10-K. On a pro forma basis that excludes the impact of any potential non-cash, non-operational expense related to the "make-good" shares, the Company reaffirmed that it me...

Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results

...uing businesses grew 7% in full year 2008 on a pro forma basis. We have strong momentum to start 2009, wit...th of approximately 3% over first quarter 2008 pro forma revenue of $26.4 million, which is before anticipa...ganic revenue growth of between 4-7% over 2008 pro forma revenue of $122.8 million, which is before anticip...

More>>

Other Tags
(Date:9/1/2014)... Wellesley, Mass., (PRWEB) September 01, 2014 ... report, BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS ... reached $21.8 million in 2013 and is expected to ... further grow to $471.5 million by 2019, which is ... 2014 through 2019. The receptor-mediated transport (RMT) segment is ...
(Date:9/1/2014)... 2014 Parties involved in federally-filed Tylenol ... litigation’s status conference in September, where issues related to ... the Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. ... posted on the Court’s website, the meeting is scheduled ... a.m. This is the latest of several Tylenol conferences ...
(Date:9/1/2014)... Ontraport , one of the latest ... to automate the small intricacies of managing an online ... prompting an investigative review. , “As a new ... all of the small details involved with running a ... “That’s why Ontraport has become so popular in this ...
(Date:9/1/2014)... AttorneyOne.com, a recognized authority on law, update ... the FDA on DePuy Synthes Craniomaxillofacial Distraction System ... 28, that specific lots of DePuy Synthes Craniomaxillofacial Distraction ... device may reverse directions after surgery. According to ... is an implant used to lengthen and/or stabilize the ...
(Date:9/1/2014)... 01, 2014 Beginning Tuesday, September 2nd, ... medical professionals and 10,000 consumers for the annual gathering ... gathering of the nation’s top medical professionals who specializes ... conditions. The week-long event contains more than 120 hours ... available in the pain management field. , MarijuanaDoctors.com is ...
Breaking Medicine News(10 mins):Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2
(Date:9/1/2014)... and decisions of the Nomenclature Section of the XVIII ... July 2011. This meeting is held every six years ... the rules for naming algae, fungi and plants get ... naming the organisms they study. This is the primary ... for algae, fungi, and plants, which was published in ...
(Date:8/31/2014)... not busy attacking us, germs go after each other. ... disaster for the infected microbes: Sometimes viruses actually carry ... expand its diet or better attack its own hosts. ... immune system would robotically destroy anything it recognized as ... have now revealed that one variety of the bacterial ...
(Date:8/29/2014)... Researchers at UC Davis have made some surprising ... infection. Studying simian immunodeficiency virus (SIV), the team ... Paneth cells are early responders to viral invasion ... producing a cytokine called interleukin-1 beta (IL-1β). ... IL-1β causes breakdown of the gut epithelium that ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3The early cost of HIV 2
Other Contents